Adverse Events Of the 15 trials, four did not report adverse event (AE) data
Cararo, J
The cost barrier is equally structural: at USD 1,000-1,300 per month without insurance, GLP-1 drugs are affordable only to a small fraction of the global population who could benefit clinically, concentrating commercial market growth in the wealthy minority of the total addressable patient population
However, when combined with GnRH (Gonadotropin-Releasing Hormone) pulses and TRH (Thyrotropin-Releasing Hormone) infusion, it has been shown to significantly increase testosterone levels, with a peak increase of up to 312% observed in Latvia studies
So I think the premise here is that by lowering BMI with these drugs before the onset of disease, you can attenuate the onset of disease
From a market perspective: Oral GLP-1 drugs may expand patient eligibility They could reduce healthcare system burden related to injections They may accelerate global adoption in regions with limited cold-chain infrastructure From a development perspective: Oral small molecules demand higher chemical precision Quality risks move upstream into intermediates and process design Manufacturing partners play a strategic, not transactional, role Our Role in Supporting Orforglipron Development As a manufacturer of pharmaceutical intermediates and APIs, we closely monitor the technical evolution of innovative molecules such as orforglipron
